Cargando…
Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
INTRODUCTION: The JAK/STAT signaling pathway is involved in the immune-mediated inflammatory skin diseases atopic dermatitis (AD), vitiligo, and alopecia areata (AA), and represents a potential target when developing treatments. So far, no drugs targeting this pathway have been approved for the trea...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828894/ https://www.ncbi.nlm.nih.gov/pubmed/31606872 http://dx.doi.org/10.1007/s13555-019-00329-y |
_version_ | 1783465445133647872 |
---|---|
author | Montilla, Ana M. Gómez-García, Francisco Gómez-Arias, Pedro J. Gay-Mimbrera, Jesús Hernández-Parada, Jorge Isla-Tejera, Beatriz Ruano, Juan |
author_facet | Montilla, Ana M. Gómez-García, Francisco Gómez-Arias, Pedro J. Gay-Mimbrera, Jesús Hernández-Parada, Jorge Isla-Tejera, Beatriz Ruano, Juan |
author_sort | Montilla, Ana M. |
collection | PubMed |
description | INTRODUCTION: The JAK/STAT signaling pathway is involved in the immune-mediated inflammatory skin diseases atopic dermatitis (AD), vitiligo, and alopecia areata (AA), and represents a potential target when developing treatments. So far, no drugs targeting this pathway have been approved for the treatment of dermatological diseases. We reviewed the use of drugs blocking the JAK/STAT pathway in the aforementioned diseases. METHODS: An a priori protocol was published. We used Joanna Briggs Institute Reviewer’s Manual methodology to conduct the review and PRISMA Extension for Scoping Review (PRISMA-ScR) to report results. MEDLINE, EMBASE, CINAHL, Scopus, and Web of Science databases were searched in a three-step approach on April 2019 by two researchers. RESULTS: Ninety-six mainly multicenter observational studies were included (66, 10, and 20 studies on AA, vitiligo, and AD, respectively). Tofacitinib and ruxolitinib were mainly used for the three diseases, and also upadacitinib, abrocitinib, baricitinib, cerdulatinib, delgocitinib, gusacitinib for AD, and baricitinib, PF-06700841, and PF-06651600 for AA. All patients with AD improved, whereas patients with vitiligo and patients with AA showed varied responses, including unresponsive cases. The safety profiles were similar for all drugs and diseases, mainly comprising mild or no adverse events. CONCLUSIONS: Evidence on the efficacy and safety of drugs targeting the JAK/STAT pathway for the treatment of patients with AD, vitiligo, or AA is increasing but is still of low quality. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13555-019-00329-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6828894 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-68288942019-11-18 Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata Montilla, Ana M. Gómez-García, Francisco Gómez-Arias, Pedro J. Gay-Mimbrera, Jesús Hernández-Parada, Jorge Isla-Tejera, Beatriz Ruano, Juan Dermatol Ther (Heidelb) Review INTRODUCTION: The JAK/STAT signaling pathway is involved in the immune-mediated inflammatory skin diseases atopic dermatitis (AD), vitiligo, and alopecia areata (AA), and represents a potential target when developing treatments. So far, no drugs targeting this pathway have been approved for the treatment of dermatological diseases. We reviewed the use of drugs blocking the JAK/STAT pathway in the aforementioned diseases. METHODS: An a priori protocol was published. We used Joanna Briggs Institute Reviewer’s Manual methodology to conduct the review and PRISMA Extension for Scoping Review (PRISMA-ScR) to report results. MEDLINE, EMBASE, CINAHL, Scopus, and Web of Science databases were searched in a three-step approach on April 2019 by two researchers. RESULTS: Ninety-six mainly multicenter observational studies were included (66, 10, and 20 studies on AA, vitiligo, and AD, respectively). Tofacitinib and ruxolitinib were mainly used for the three diseases, and also upadacitinib, abrocitinib, baricitinib, cerdulatinib, delgocitinib, gusacitinib for AD, and baricitinib, PF-06700841, and PF-06651600 for AA. All patients with AD improved, whereas patients with vitiligo and patients with AA showed varied responses, including unresponsive cases. The safety profiles were similar for all drugs and diseases, mainly comprising mild or no adverse events. CONCLUSIONS: Evidence on the efficacy and safety of drugs targeting the JAK/STAT pathway for the treatment of patients with AD, vitiligo, or AA is increasing but is still of low quality. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13555-019-00329-y) contains supplementary material, which is available to authorized users. Springer Healthcare 2019-10-13 /pmc/articles/PMC6828894/ /pubmed/31606872 http://dx.doi.org/10.1007/s13555-019-00329-y Text en © The Author(s) 2019 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Montilla, Ana M. Gómez-García, Francisco Gómez-Arias, Pedro J. Gay-Mimbrera, Jesús Hernández-Parada, Jorge Isla-Tejera, Beatriz Ruano, Juan Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata |
title | Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata |
title_full | Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata |
title_fullStr | Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata |
title_full_unstemmed | Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata |
title_short | Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata |
title_sort | scoping review on the use of drugs targeting jak/stat pathway in atopic dermatitis, vitiligo, and alopecia areata |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828894/ https://www.ncbi.nlm.nih.gov/pubmed/31606872 http://dx.doi.org/10.1007/s13555-019-00329-y |
work_keys_str_mv | AT montillaanam scopingreviewontheuseofdrugstargetingjakstatpathwayinatopicdermatitisvitiligoandalopeciaareata AT gomezgarciafrancisco scopingreviewontheuseofdrugstargetingjakstatpathwayinatopicdermatitisvitiligoandalopeciaareata AT gomezariaspedroj scopingreviewontheuseofdrugstargetingjakstatpathwayinatopicdermatitisvitiligoandalopeciaareata AT gaymimbrerajesus scopingreviewontheuseofdrugstargetingjakstatpathwayinatopicdermatitisvitiligoandalopeciaareata AT hernandezparadajorge scopingreviewontheuseofdrugstargetingjakstatpathwayinatopicdermatitisvitiligoandalopeciaareata AT islatejerabeatriz scopingreviewontheuseofdrugstargetingjakstatpathwayinatopicdermatitisvitiligoandalopeciaareata AT ruanojuan scopingreviewontheuseofdrugstargetingjakstatpathwayinatopicdermatitisvitiligoandalopeciaareata |